iPSirius is pioneering the use of Induced Pluripotent Stem Cells (iPSC) to develop innovative immunotherapies aimed at combating aggressive cancers. Their approach focuses on addressing significant challenges in cancer treatment, such as metastasis, treatment resistance, and relapse. By utilizing their proprietary technology, IPVAC 1.0, iPSirius enhances the immune system's ability to recognize and respond to cancer stem cells (CSC), which are known to contribute to tumor initiation and progression. This technology not only targets the antigens present in CSC but also aims to transform the immunosuppressive tumor microenvironment into one that is more conducive to immune activity, thereby improving the efficacy of the immune response against cancer cells.

The company is actively developing a range of therapeutic products designed to treat various late-stage cancers, including non-small cell lung cancer, glioblastoma, triple-negative breast cancer, and pancreatic cancer. These products can be administered alone or in combination with other therapies to bolster anti-tumor immunity, ultimately enhancing patient prognoses and expanding therapeutic options. iPSirius's commitment to advancing cancer treatment through iPSC-based immunotherapy represents a significant step forward in the fight against cancers that are resistant to conventional therapies.

France

iPSirius SAS, [pronounced ip-Sirius], is a French headquartered immuno-oncology firm, seeking to obtain a clinical trial authorization from the U.K.’s Medicines and Healthcare Regulatory Products Agency, to enable it to move its novel therapeutic cancer vaccine into a first-in-human trial in patients with non-small-cell lung cancer.

iPSirius

Company Details